Amgen and Allergan plc . announced that the European Commission (EC) has granted marketing authorization for MVASI (biosimilar bevacizumab). MVASI...
Amgen and Allergan plc announced that Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin...
Amgen and Allergan announced that the FDA has approved Mvasi (bevacizumab-awwb) for all eligible indications of the reference product, Avastin...